Telix Pharmaceuticals (TLX) Receivables (2023 - 2025)

Telix Pharmaceuticals (TLX) has 3 years of Receivables data on file, last reported at $1.3 million in Q4 2025.

• Receivables for Q4 2025 came in at $1.3 million, down 98.62% year-over-year; the trailing twelve-month figure through Dec 2025 was $1.3 million (down 98.62% YoY), and the FY2025 annual result was $1.3 million, down 98.62% from the prior year.
• Receivables eased to $1.3 million in Q4 2025 per TLX's latest filing, from $93.0 million in the prior quarter.
• Over five years, Receivables peaked at $93.0 million in Q4 2024 and troughed at $1.3 million in Q4 2025.
• A 3-year average of $46.0 million and a median of $43.7 million in 2023 frame the typical range for Receivables.
• The sharpest annual moves came in 2024 and 2025: Receivables surged 112.85% in 2024, then tumbled 98.62% in 2025.
• A 3-year view of Receivables shows it stood at $43.7 million in 2023, then surged by 112.85% to $93.0 million in 2024, then plunged by 98.62% to $1.3 million in 2025.
• Business Quant data shows TLX's Receivables at $1.3 million in Q4 2025, $93.0 million in Q4 2024, and $43.7 million in Q4 2023.